Evidence map›Paper›PMID 33932148›Full record

ReviewACR open rheumatology2021

Testing the Effects of Disease-Modifying Antirheumatic Drugs on Vascular Inflammation in Rheumatoid Arthritis: Rationale and Design of the TARGET Trial.

Jon T Giles, Pamela M Rist, Katherine P Liao, Ahmed Tawakol, Zahi A Fayad, Venkatesh Mani, Nina P Paynter, Paul M Ridker, Robert J Glynn, Fengxin Lu and 5 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in ACR open rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Jon T GilesColumbia University, Vagelos College of Physicians & Surgeons, New York, New York.ORCID https://orcid.org/0000-0002-8792-0402
Pamela M RistBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Katherine P LiaoBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0002-4797-3200
Ahmed TawakolMassachusetts General Hospital and Harvard Medical School, Boston.
Zahi A FayadTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York.
Venkatesh ManiTranslational and Molecular Imaging Institute, Icahn School of Medicine at Mount Sinai, New York.
Nina P PaynterBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Paul M RidkerBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Robert J GlynnBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Fengxin LuBrigham and Women's Hospital, Boston, Massachusetts.
Rachel BroderickColumbia University, Vagelos College of Physicians & Surgeons, New York, New York.
Meredith MurrayBrigham and Women's Hospital, Boston, Massachusetts.
Kathleen M M VanniBrigham and Women's Hospital, Boston, Massachusetts.ORCID https://orcid.org/0000-0003-0839-9661
Daniel H SolomonBrigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.ORCID https://orcid.org/0000-0001-8202-5428
Joan M BathonColumbia University, Vagelos College of Physicians & Surgeons, New York, New York.
Brigham and Women's Hospital · USColumbia University · USImaging Center · USHarvard University · US

Funding

Treatments Against RA and Effect on FDG PET CT: The TARGET TRIALU01AR068043 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BATHON, JOAN MARIE, SOLOMON, DANIEL HAL · 2015 to 2021
$8.7M
Treat to Target to Reduce Atherosclerosis in Rheumatoid ArthritisU34AR063911 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI BATHON, JOAN MARIE, SOLOMON, DANIEL HAL · 2013 to 2014
$720k
NIAMS NIH HHS U01 AR068043NIAMS NIH HHS U01AR068043NIAMS NIH HHS U34 AR063911NIAMS NIH HHS U34AR063911
6 · The paper itself

Abstract

Individuals with rheumatoid arthritis (RA) are at increased risk for atherosclerotic cardiovascular disease (ASCVD) events relative to the general population, potentially mediated by atherosclerotic plaques that are more inflamed and rupture prone. We sought to address whether RA immunomodulators reduce vascular inflammation, thereby reducing ASCVD risk, and whether such reduction depends on the type of immunomodulator. The TARGET (Treatments Against RA and Effect on 18-Fluorodeoxyglucose [

Identifiers

PMID33932148
PMCPMC8207684
OpenAlexW3158090859

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.